Navigation Links
IDRI Develops Novel Tuberculosis Vaccine, New Study in Science Reports
Date:10/15/2010

SEATTLE, Oct. 16 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces it has developed a new tuberculosis (TB) vaccine that protects against TB including drug-resistant strains of the disease in animal studies. The results of these studies are published in Science Translational Medicine today.

Drug-resistant tuberculosis is a major global public health concern. According to the World Health Organization, approximately 9 million people are infected with TB, and close to half a million are resistant to multiple drugs that once effectively treated the disease. Two million people die of TB each year.

Though a childhood vaccine for tuberculosis, BCG, has been widely used for decades, its protection wanes over time, and new virulent forms of the disease are spreading. Control activities are limited without new vaccines, immunotherapeutics, and drugs to protect against these killer strains of TB.

IDRI's TB vaccine enhances and extends BCG and protects against drug-resistant strains through its unique combination of a molecule containing four tuberculosis proteins with a synthetic adjuvant, also developed at IDRI.

Dr. Rhea Coler, Vice President of Preclinical Biology and one of the study's Principal Investigators, explains, "Combining proteins in a vaccine is important because tuberculosis bacilli are variable, and no single protein will be effective against all strains."  In addition, because of human genetic diversity, individuals will respond differently to different proteins. A combination of proteins, such as exist in natural tuberculosis bacteria, increases the vaccine's efficacy.

The vaccine is now being developed for clinical testing in humans.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities—including preclinical vaccinology, manufacturing, and clinical trials—IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most.

For more information, go to www.idri.org  


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
2. Nventa Develops Proprietary Vaccine Adjuvant
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
5. Binghamton Research Group Develops New Cancer Treatment
6. Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications
7. Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
8. HDT Develops Robotic Arm Technology for DARPAs Revolutionizing Prosthetics 2009 Program
9. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
10. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
11. Varian Medical Systems Develops New X-Ray Tube for Use in Security Scanning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s ... June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... helping service members that have been wounded in battle and their families. Venture Construction ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Today, InhaleLabs.com ... the ingestion of their medication by matching users with high quality water pipes within ... pieces with no commitment. , Inhale was founded by two brothers, Nick and Mike ...
Breaking Medicine News(10 mins):